- Home
- TAC vs VKTX Comparison
TAC vs VKTX Comparison
Compare TAC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | VKTX |
|---|---|---|
| Founded | 1909 | 2012 |
| Country | Canada | United States |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | TAC | VKTX |
|---|---|---|
| Price | $13.98 | $37.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $23.67 | ★ $95.86 |
| AVG Volume (30 Days) | 1.1M | ★ 3.0M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $22.96 |
| 52 Week High | $17.88 | $43.15 |
Technical Indicators
Market Signals| Indicator | TAC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 55.55 |
| Support Level | $13.37 | $32.66 |
| Resistance Level | $14.03 | $39.78 |
| Average True Range (ATR) | 0.45 | 2.23 |
| MACD | -0.05 | -0.46 |
| Stochastic Oscillator | 53.89 | 34.93 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.